International Journal of Pharmacy and Pharmaceutical Science

ISSN Print: 2664-7222
ISSN Online: 2664-7230
IJPPS 2024; 6(1): 10-19
www.pharmacyjournal.org
Received: 13-11-2023
Accepted: 21-12-2023

Ashish Shivram Ramteke
Visvesvaraya National Institute of Technology, Nagpur, Maharashtra, India

Corresponding Author:
Ashish Shivram Ramteke
Visvesvaraya National Institute of Technology, Nagpur, Maharashtra, India

Mechanism, potency and restriction of anti-CTLA-4 and anti-PD-1 immunotherapies in cancer

Ashish Shivram Ramteke

DOI: https://doi.org/10.33545/26647222.2024.v6.i1a.75

Abstract
Melanoma and some other cancers identified with high fatality rates which are highly radio and chemotherapy resistant yet may be very immunogenic. These factors have showed to a current surge in research into therapies focusing to boost anticancer immune responses in patients. Beside these therapies, neutralizing antibodies targeting the immune checkpoints cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are being approached as specifically successful. Although, the most of advanced stage melanoma patients ignore, and the search for the "magic bullet" to treat the disease continuously. Anti-PD-1/PD-L1 and anti-CTLA-4 antibodies are the two types of checkpoint inhibitors currently available to melanoma and other cancer patients.

Keywords: Immunoglobulins, CD28, Immune checkpoints, T-cells, Cancer

Introduction

In present days, there has been a step forward towards the implementation and improvement of cancer immunotherapies. The approval of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies for human use has already reported in considerable improvements in disease outcomes for several types of cancers, generally melanoma [1]. Radiotherapy and chemotherapy focus to directly interfere with cancer growth and survival, whereas immunotherapies target cancer indirectly through boosting the anticancer immune responses that are already existing in several cancer patients [2].

Acknowledge the manner of activity of immune checkpoint blockers, it is significant to appreciate the active interplay between the immune system and cancers in the time of the disease. Cancer cells are genetically abnormal, contributes to their uncontrolled proliferation and the antigens expression that may be recognized through the immune system [3]. These antigens involve general proteins overexpressed through cancer cells and novel proteins that are created through gene rearrangement and mutation. Cytotoxic ($CD8^+$) T-cells are immune cells that are specifically effective at moderating anticancer immune responses [4].

These immune cells can recognize the cancer-associated antigens expressed on major histocompatibility complex (MHC) class I molecules, proceeding to cancer cell killing. $CD8^+$ T-cells become authorized effector cells after appropriate activation through antigen presenting cells (APCs) that have engaged with antigens at the cancer site [5]. Besides the antigen presented on the MHC molecules, APCs must produce costimulatory signals by surface receptors (such as CD28) and cytokines like interleukin (IL)-12 for effective T-cell stimulation [6]. Cancer cells accept a range of mechanisms to evade immune recognition and mediated destruction. Expected cancers are often believed to arise by the selection of clones that are capable to avoid the immune system, a process called as immunoediting [7].

Cancer cells may avoid immune recognition directly through downregulating characteristics that make immune cells defenseless, like MHC class I or cancer antigens. Moreover, cancers can avoid immune responses through taking advantage of negative regulations that the body has evolved to prevent immunopathology [8]. These involve inhibitory cytokines like IL-10, Transforming growth factor-β (TGF-β), and also inhibitory cells like regulatory T-cells and B-cells, myeloid derived suppressor cells, metabolic regulators like indoleamine 2,3-dioxygenase, and inhibitory receptors like CTLA-4 and PD-1 [9].

Immune depletion and dysfunction in cancer

Immune checkpoints and their ligands may be expressed on a variety of cells. They are necessary for central and peripheral tolerance in that they prevent concurrent activating signaling by co-stimulatory molecules. Inhibitory receptors can react during both immune activation and ongoing responses [10]. At specific time of chronic inflammation, T-cells are called to become exhausted and to upregulate a broadly various of non-redundant inhibitory receptors that limit their efficaciousness, like CTLA-4, PD-1, T-cell immunoglobulin and mucin domain 3, lymphocyte activation gene 3, or T-Cell immunoreceptor with immunoglobulin domains (Table 1) [11].

Table 1: Summary of T-cell receptors linked with immune inhibition

Receptor	Expressing cells	Ligands	Ligand-expressing cells
CTLA-4	CD4, CD8, cancers	CD80, CD86	APCs
PD-1	CD4, CD8, B-cells, mast cells, monocytes, Langerhans cells	PD-L1, PD-L2	APCs, CD4+ T-cells, cancers
LAG-3	CD4, CD8, NK cells	MHC II	APCs, cancers
TIM-3	CD4, CD8, NK cells, DCs, monocyte, macrophage	Galectin-9, phosphotidyl serine	Endothelial cells, apoptotic cells, cancers

In the situation of chronic viral infections, where the host failures to clear the pathogens, it is now observable that exhausted T-cells may occur in cancer. It is thought that, under these circumstances, persistent high antigenic load shows to the T-cells upregulating the inhibitory receptors, which signaling eventually shows to a progressive proliferative potential loss and effector functions or in some instances to their deletion [12]. Physiological functions happening to limit immunopathology during persistent infection and barrier for anticancer immune responses, leads to immune cells exhaustion. While expression of inhibitory molecular markers is not always an indication of immune exhaustion, the receptors can be expressed alone during normal immune responses [13].

CTLA-4 immune checkpoint receptor

The ipilimumab, CTLA-4 inhibiting antibody was the first immune checkpoint blocker to be examined and authorized for the treatment of cancer patients. As a B7/CD28 family member, CTLA-4 (CD152) that prevents T -cell functions. It is fundamentally presented through Tregs, however may be upregulated through other T-cell subsets, generally $CD4^+$ T-cells activation [14]. Exhausted T-cells are often featured through the expression of CTLA-4 between another inhibitory receptors. CTLA-4 is commonly situated in intracellular vesicles and temporarily presented upon activation in the immunological connection before being quickly endocytosed [15].

CTLA-4 mediates immunosuppression through indirectly declining signaling by the co-stimulatory receptor CD28. While both receptors bind to CD80 and CD86, CTLA-4 does so with much greater affinity, beneficially outcompeting CD28 [16]. CTLA-4 can flush CD80 and CD86 (involving cytoplasmic domains) from the cell surfaces of APCs through trans-endocytosis, hence decreasing the availability of these stimulatory receptors to other CD28 presenting T-cells. In fact, this process is a significant mechanism through which Tregs mediate immune suppression on neighboring cells [17].

Through arresting CD28 mediated signaling during antigen presentation, CTLA-4 rises the activation threshold of T-cells, lowering immune responses to weakly antigens like individual and cancer antigens. The intermediate role that CTLA-4 plays in immunological tolerance is represented through trials in rats that deficit the CTLA-4 gene globally or particularly in the $FoxP3^+$ Treg compartment [18]. These creatures develop lymphoproliferative disorders and be lost at an immature stage. Likewise, polymorphisms in the CTLA-4 gene are linked with autoimmune diseases in humans. CTLA-4 signaling has been seen to reactive immune responses to infections and cancer cells [19].

PD-1 immune checkpoint receptor

The receptor PD-1 (CD279) was earliest found on a murine T-cell hybridoma and believed to be responded in cell death. However, it has become clear that PD-1 is homologous to CD28, which is firstly included in inhibitory immune signaling and also significant enhancer of adaptive immune responses [20]. In humans and rats certain T-cell populations constitutively present PD-1, such as follicular helper T-cells. While most of circulating T-cells don't express the receptor, they can be introduced upon stimulation by the T-cell receptor or interleukins exposure (IL-2, IL-7, IL-15, IL-21) and transforming growth factor-β [21].

Further immune cells like B-cells, myeloid dendritic cells, mast cells, and Langerhans cells may express PD-1 to balance their individual and passerby cell functions under pathophysiological situations [22]. PD-1 has two ligands [PD-L1 (B7-H1; CD274), PD-L2 (B7-DC; CD273)], which may be expressed on the cell surface of APCs (like dendritic cells, monocytes, and macrophages), nevertheless otherwise diversely presented on different non-lymphoid tissues. Interferon-γ (IFN-γ) is the major trigger investigated to cause PD-L1 and PD-L2 upregulation [23].

PD-1 carries an immunoreceptor tyrosine-based inhibition and switch motif on its intracellular tail. The intracellular signaling incidents started upon PD-1 engagement in T-cells (Fig. 1) [24]. Due to engagement of PD-1, tyrosine residues to become phosphorylated and initiating an intracellular signaling cascade that interferes the dephosphorylation of TCR proximal signaling components. In the attendance of TCR stimulation, CD28 has produces critical signals that are significant for T-cell activation and recently noticed that to be primary target [25].



Fig 1: PD-1 mediated intracellular signaling incidents during T-cell activation

Through disrupting primary TCR/CD28 signaling and related IL-2 dependent positive feedback, PD-1 signaling leads to lowered cytokine production (IL-2, IFN-γ, TNF-α), cell cycle improvement, and decreased expression of the transcription factors included in effector functions [26]. PD-1 activity is only related in simultaneous T-cell activation, as its signal transduction may only induce effect during TCR dependent signaling. Investigation of PD-1 signaling in other cells that carries this surface receptor, like B-cells, hold on to be resolved [27].

PD-1 is critical for the peripheral tolerance maintenance and containing immune responses to evade immunopathology. The receptor primarily appears well, however create autoimmune diseases like arthritis with age, lupus proliferative glomerulonephritis and exacerbated inflammation during infections. Humans with genetic polymorphisms in the PD-1 locus have raised possibility of developing several autoimmune diseases [28].

CTLA-4, PD-1/PD-L1 and their ligands

CTLA-4 can be presented in cancer lesions on infiltrating Tregs or exhausted normal T-cells and individual cancer cells. In spite of the immunosuppressive character of CTLA-4, its relation with disease prognosis is unclear [29]. Moreover, it should be reported that only some minor investigations have illustrated the prognostic value of CTLA-4 levels in the cancer locate. PD-1 may be upregulated transiently during stimulation or fundamentally during chronic immune activation [30].

The inhibitory receptor has been investigated on both circulating cancer specific T-cells and cancer infiltrating lymphocytes, it was led with lowered T-cell function showed in humans and rats. For instance, PD-1 positive dendritic cells have been reported in hepatocellular carcinoma where they showed a decreased capability to stimulate T-cells [31]. Further investigation reported a population of cancer infiltrating PD-1 expressing regulatory B-cells that released IL-10. higher amounts of these cells were coordinated with unsatisfactory disease outcome in hepatocellular carcinoma patients. Cancer related macrophages were recently seen to present PD-1 in both human and rat with colorectal cancer and to decrease phagocytosis [32].

Cancer cells and cancer infiltrating immune cells like macrophages can present PD-L1 and upregulate it in response to IFN-γ. PD-L1 expression can be sign of active anticancer immune responses and actively provide to normal immunosuppression [33]. The relation between PD-1 or PD-L1 expression at the cancer location and disease outputs is thus not compatible beside all cancers and patients. PD-1 or PD-L1 can relate with deficient prognosis in certain cancers (involving melanoma, renal cell carcinoma, esophageal, gastric, and ovarian cancers) and with bettered prognosis in others (like angiosarcoma and gastric cancer) [34].

Effectiveness and action mechanism of checkpoint blockers

CTLA-4 and PD-1 immune blockers have reported in improved patient survival in a number of investigations (involving melanoma, renal cell carcinoma, squamous cell carcinoma, and non-small cell lung cancer) when compared to normal chemotherapies (Table 2). Anti-PD-1 treatment in melanoma was more helpful with smaller cancers patients [35]. Comparison between the two checkpoint blockers in a Phase III trial showed significant response and survival rates (44% and 6.9 months) beside patients introduced with the anti-PD-1 nivolumab than other those administered with the anti-CTLA-4 ipilimumab (19% and 2.8 months) [36].

Table 2: Treatment conclusion of clinical trials for immune checkpoint blockers in several cancers

Target	Drug	Condition	Treatment regimen	Overall survival	Progression free survival	Grad 3-5 adverse events	Participants treated
PD-1	Nivolumab (IgG 4a)	Melanoma	3mg/kg/2w	n/a	6.9	16.3%	316
	Pembrolizumab (IgG 4a)	Merkel cell carcinoma	2mg/kg/3w	n/a	65% (6 month)	15%	26
	Pidilizumab (IgG 1)	B-cell lymphoma	1.5 mg/42 days	85% (16 month)	72% (16 month)	n/a	66
PD-L1	Atezolizumab (IgG 1)	Non-small cell lung cancer	1200 mg/3 w	15.7	2.8	15%	425
CTLA-4	Ipilimumab (IgG 1)	Melanoma	10 mg/kg + decarbazine	11.2	n/a	56.3%	250
	Tremelimumab (IgG 2)	Melanoma	15 mg/kg/90 days	12.6%	20.3%	52%	328
Combine therapy	Nivolumab + Ipilimumab	Melanoma	3 mg/kg/2 w + 3 mg/kg/3 w	n/a	11.5	55%	314

Dual introduction of nivolumab and ipilimumab investigated in even higher response and survival rates (58% and 11.5 months). CTLA-4 and PD-1 react individually as slows down CD3/CD28 dependent signaling, recommending that primary immune responses are required for checkpoint blockers treatment to take result [37]. In fact, both CTLA-4 and PD-1 inhibitions are more significant in cancers that are invaded through T-cells or that have high mutation rates and more immunogenic earlier to treatment. The direct immunological effects of anti-CTLA-4 and anti-PD-1 treatments have primarily been explored in T-cells (Figure 2) [38].



Fig 2: The role of CTLA-4 and PD-1 in the priming and effector phases of anticancer immune responses

The inhibition of CTLA-4 favorable possible effects the T-cell activation stage in the clearing lymph nodes when CTLA-4 presenting Tregs withdraw CD80/CD86 from the surface of APCs, while lowering their capacity to significantly stimulate cancer particular T-cells. CTLA-4 inhibition can take impact at the cancer location as exhausted CTLA-4 introducing T-cells and Tregs can gather in the cancer microenvironment [39]. PD-1 presenting cancer infiltrating T-cells may be impaired through PD-L1 on the cells surface of cancer or further infiltrating immune cells. Inhibiting antibodies targeting PD-1 signaling are viewed to generally affect the effector step of the immune response [40].

Further cells like dendritic cells and B-cells may be affected through PD-1 signaling, the PD-1/PD-L1 blockade pathway can also have T-cell independent impacts, whose effect on immune responses during checkpoint blockade therapy left to be illuminated. Type I immune responses involve IFN-γ secretion and cytotoxic T-cell functions are essential for active anticancer immune responses [41]. They are related with superior responses to anti-CTLA-4 and anti-PD-1 treatments. Recently, mouse models have experienced that common IFN-γ upregulation is preferable for anti-PD-1 mediated cancer regression. IFN-γ and the cytotoxic granule component granzyme B were raised in regressing melanoma patient trauma after anti-PD-1 treatment [42].

Patients with cancers introduced with anti-PD-1 who primarily responded. Investigated mutations that led a consecutive loss in MHC I surface expression to evade cytotoxic T-cell expression or in IFN-γ response elements. Th9 $CD4^+$ T-cells have been recommended to conduct a role according to a present evaluation that exposed a rise in Th9 cell occurrence in patients acknowledging to anti-PD-1 treatment [43]. It can be appealing to suspect that immune checkpoint blockers particularly improve the T-cells function belonging to the effector memory compartment. These cells normally present cytotoxic molecules (like perforin and granzyme B). Hence, these cells insufficient the co-stimulatory receptor CD28 by which both CTLA-4 and PD-1 block T-cell function [44].

Present investigations have seen that it is certainly CD28 expressing cells alternative previously lethally differentiated effector cells that lead to PD-1 inhibition with a proliferative burst and differentiation. The features of a cancer itself can also impact immune checkpoint blocker efficiency. The mutational nature of cancer cells can increase their antigenicity, however can boost their capacity to provoke treatment introduced immune responses [45]. A present investigation explored a melanoma gene signature related with innate anti-PD-1 resistance, involved upregulation of genes led with angiogenesis, wound healing, cell adhesion, mesenchymal transitioning, and extracellular matrix remodeling. Symbiotic bacteria can also contain a key role in impacting the efficiency of immune checkpoint blockers [46].

Anti-CTLA-4 treatment was showed to be ineffectual in rats raised under sterile conditions and to introduce a shift in the gut flora of generally raised rats. Experiments evaluated that the reveal of several bacterial strains, in specific Bacteroides fragilis, promoted Th1 polarization in the mammals and was led with boosted anticancer immune response [47]. Antibiotic treatment was also correlated with lowered responses to anti-PD-1/PD-L1 treatments in cancer patients, which is feasibly through changing the normal gut flora. Favorable treatment response among patients was rather connected with the presence of the symbiotic bacterial supplement, which boosted anti-PD-1 treatment responses in rats through permitting raised availability of $CCR9^+$ $CXCR3^+$ $CD4^+$ T-cells into the cancer [48].

Unfavorable therapeutics events and their supervision

CTLA-4 and PD-1 arrest autoimmunity and restrict immune activation block passerby damage under physiological conditions. Blockade of these receptors by therapeutic antibodies for the treatment of cancer is connected with a wide variety of side consequences that favor autoimmune reactions. Rates of acute side effects differ greatly through investigation and treatment (Table 2) [49]. Clinical trials that directly compared various types of immune checkpoint blockers and their combination reported that more patients explored side effects when introduced with anti-CTLA-4 (27.3%) compared to anti-PD-1 (16.3%). Even more patients were impressed when introduced with a combination (55%) [50].

Most of the patients introduced with immune checkpoint blockers undergo diarrhea, fatigue, pruritus, rash, nausea and decreased appetite. Critical adverse effects involve colitis, raised alanine aminotransferase levels, inflammation pneumonitis, and interstitial nephritis. There have been patient's records undergoing increasing of pre-existing autoimmune diseases like psoriasis or developing new ones like diabetes mellitus (type I) [51]. Specifically acute side effects can require treatment interruption, whilst these patients can response still thereafter. Amazingly, particular treatment associated autoimmune reactions like rash and vitiligo have been seen to coordinate with improve disease prognosis, recommending an overlap between autoimmune and anticancer immune responses [52].

Anti-CTLA-4 and anti-PD-1 biomarkers treatment efficiency

Molecular markers are required both before and during treatment to recognize the patients most or small possible to respond to immune checkpoint blocker treatments in order to lower unsuitable drug disclosure. Treatment response is defined as a decrease in cancer population during the treatment trail [53]. The factors related in disease prognoses with untreated patients are connected to checkpoint blocker response rates (Table 3). For instance, patients with smaller cancers or low serum lactate dehydrogenase (LDH) levels at baseline have a superior prognosis and more expected to reply to anti-PD-1 treatment [54].

Table 3: Molecular biomarkers analogous with positive responses to immune checkpoint blockers

	Pre-treatment	Post-treatment
Cancer	Cancer size and distribution PD-L1 expression on Cancer cells	Reduction in Cancer size
Cancer infiltrating immune cells	$CD8^+$ T-cells inside the cancer or margin PD-L1 expression by infiltrating cells	Proliferation of intra- cancerous $CD8^+$ T-cells
Circulation	High relative lymphocyte count High relative eosinophils count High serum TGF-β levels Low serum LDH level Low level of ccDNA	Increased levels of $ICOS^+$ T-cells Low neutrophil to lymphocyte ratio High levels of Th9 cells A reduction in serum LDH level A reduction in ccDNA

A depletion in LDH levels after treatment is related with bettered response. Circulating cancer DNA (ccDNA) contains melanoma alike mutations and may be liberated through dead cancer cells to be reported in some patient's serum levels coordinate actively with cancer load and progression [55]. A current investigation in advanced stage melanoma patients introduced with anti-PD-1 alone or in combination with anti-CTLA-4 illustrated high treatment response rates in independents that were ccDNA negative earlier to or after treatment, creating serum ccDNA an fascinating marker before and during checkpoint treatment [56].

For anti-PD-1 treatments, expression of PD-L1 in the cancer microenvironment has been an evident biomarker candidate. While PD-L1 expression on cancer cells was connected with treatment efficiency in melanoma patients, it wasn't in patients with squamous cell carcinoma, Merkel cell carcinoma and non-small cell lung cancer [57]. Amazingly, investigation evaluating the PD-L1 role in cancer cells and infiltrating immune cells showed that only in the concluding context was anti-PD-L1 treatment efficacy related with PD-L1 expression. The neoantigens showing on mutated cancer cells enhances anticancer immunogenicity and boosts treatment efficiency [58].

High genetic variance between cancer cells and host cells is marker of checkpoint blocker treatment efficiency. This was specifically reported in anti-CTLA-4 treated melanoma patients whose cancers expressed neo-antigens and likewise in anti-PD-1 treated patients with colorectal cancers or non-small cell lung cancers that were conflict repair defective or had high mutation rates. While overall mutational load is correlated with enhanced response to anti-PD-1 treatment, decreased responses were reported in melanoma patients whose cancers presented the IPRES gene identity [59].

Antigen display through the host can play an important role during anti-PD-1 treatment, as patients with the HLA-A*26 were more than double as possible to reply than patients negative for the allele. Further pretreatment immunological features related with progressed treatment responses involve high eosinophil and lymphocyte blood counts [60]. An plenty of $CD8^+$ T-cells infiltrating the cancer or present at the cancer outline, and raised serum TGF-β levels in melanoma patients introduced with anti-PD-1. Increased Th1 and CTLA-4 gene expression levels were reported in responder patients with several solid cancers involving melanoma treated with anti-PD-L1 [61].

A several of post-treatment immunological examinations have been related with enhanced immune checkpoint blocker responses. For instance, patients more favorable to respond to anti-CTLA-4 treatment had raised numbers of introducible costimulatory molecule displaying T -cells and decrease neutrophil to lymphocyte proportions [62]. Rise in $CD8^+$ T-cell proliferation in the cancer trauma and raised frequency of Th9 cells in the patients' circulation were linked with treatment response. These various investigations show that immune checkpoint blockers are most significant in patients who already express anticancer immune processes earlier to therapy [63].

Although, some markers suggested here can be unequally significant, and patients can quiet reply to treatment against contrary biomarker-based forecasts. Additionally, examining cancer tissue can be difficult in several patients particularly after treatment, and lower intruding blood-based "liquid biopsies" can be more suitable [64]. Mostly, it has been seen that exploring several biomarkers in combination may enhance treatment predictions. While the currently found ccDNA looks to be a specifically promising biomarker candidate, proper investigations are needed to identify more important biomarkers or its combinations to develop the most suitable treatment strategy for individual patient [65].

Restriction of immune checkpoint blockers

While immune checkpoint blocker treatment can be primarily valuable, most patients will finally lapse and create cancer progression. The selection pressure due to checkpoint blocker treatment can lead increase to cancer cells that may provoke immuno-mediated recognition and elimination by new strategies [66]. Cancer cells from patient refractory to anti-PD-1 treatment were recently seen to have obtained mutations making them less exposed to T-cell mediated killing through loss of IFN-γ response elements or MHC class I [67].

Anti-CTLA-4 and anti-PD-1 treatment can leads to upregulation of some inhibitory receptors. For instance, patients with melanoma or prostate cancer expressed upregulation of the inhibitory receptor V-domain Ig suppressor of T-cell activation on several cancer infiltrating immune cells after anti-CTLA-4 treatment [68]. Further investigation reported the upregulation of the inhibitory receptor TIM-3 on the T-cells surface in anti-PD-1 treated rats with lung cancer and also TIM-3 upregulation on T-cells in adenocarcinoma patients refractory to PD-1 treatment [69].

Latterly, an investigation disclosed further unpredictable resistance mechanism to anti-PD-1 blockade in mice by which cancer related macrophages flushed the therapeutic antibody from the T-cells surface *in vivo*, hence leading them again sensitive to inhibitory signaling by the receptor [70]. This incident could be partly control through introduction of Fc-receptor inhibiting agents earlier to treatment. A greater recognizing of the mechanisms restricting the efficacy of immune checkpoint blockers will permit better enhancement of future treatments [71].

Future prospectus and approach

CTLA-4 and PD-1 inhibiting agents are ineffective in all patients as well as despite who do reply primarily may lapse, marking the require for boosted or possible treatments. Further inhibitory receptors have been recognized that can be targeted for anticancer immune therapy [72]. These involving the TIM-3, LAG-3, TIGIT, B-cell and T-cell related protein receptors connected with T-cell exhaustion. V-domain Ig suppressor of T-cell activation, receptor expressed on cancer infiltrating myeloid cells blocking assisted anticancer immune responses in murine models and CD96 has been displayed to block NK cell activity in murine cancer models [73].

The anti-CTLA-4 and anti-PD-1 combination treatments resulted greater efficiency compared to each introduction, although was led with rise in side effects. The tryptophan metabolizing enzyme IDO interrupt T-cell function, and combining IDO-inhibiting agents together with immune checkpoint blockers has reported possible outcomes in rats and is also recently ongoing clinical trials in humans. Macrophages (phagocytic cell) can also interconnect with anticancer immunity or even directly distract therapeutic antibodies [74].

Their exhaustion by a colony stimulating factor 1 receptor blocker is being reported in clinical trials together with anti-PD-1, after having recorded efficiency in a glioblastoma rat model. Anticancer T-cell function administered through PD-1 inhibition in rats could be enhanced through a targeted rise in mitochondrial function. Due to immune checkpoint blockers work through eliminating brakes on the immune system beside than directly enhancing immune function, patients can also advantage from combined immunotherapies that involve immunostimulatory substances [75].

For instance, rat melanoma models have investigated that the anti-CTLA-4 combine with cytokines like granulocyte macrophage colony stimulating factor (GM-CSF) or with aggressive antibodies targeting costimulatory receptors like CD40, which raised cancer elimination in a symbiotic manner. The genetically modified herpes simplex virus is planned to replicate in cancer cells and to liberate GM-CSF, hence attracting immune cells into the cancer environment. The virus has been explored in current clinical trials in combine with either CTLA-4 or PD-1 in progressive stage melanoma patients, leading in raised treatment response rates compared to the individually immune checkpoint blockers [76].

Regulation of the gut microbiome can enhance immune checkpoint blocker-based therapies. induction of each intestinal bacteria was marked with lowered cancer growth in a murine B16 melanoma model through enhancing dendritic cell mediated $CD8^+$ T-cell responses. The introduction of these bacteria also supplemented to the therapeutic impact of anti-PD-1 treatment in these rats. Similarly, introduction of B. fragilis to sterile rats managed with anti-CTLA-4 led in lowered cancer growth, more probably through introducing a possible shift toward Th1 responses [77].

Further investigations in humans were capable to connect the presence of several bacterium to a possible result to anti-PD-1 treatment. Together, these detections recommend that human patients too can advantage from suitable management of their intestinal flora whereas ongoing immune checkpoint blocker treatment. A variety range of pledging new directions are recently being reported, while their clinical efficiency rests to be confirmed by ongoing and future clinical trials [78].

Conclusion

While CTLA-4 and PD-1 targeting therapies have been capable to improve standard life expectation for cancer patients, mortality remains high one of advanced stage patients, attracting the requiring for some innovation in the area. Anti-CTLA-4 and anti-PD-1 therapies emerge to be more functional in patients with pre-existing anticancer immunity, recommending that patients without such immunity, these therapeutics are unfit to intervene anticancer immune responses *de novo*. Although our conception of the mechanisms of these therapeutics enhances, directions are being opened to boost their utilization not only through particularly targeting those patients who are most likely to respond by suitable biomarker screening methods, but also through coupling recently used immune checkpoint blockers with other equivalent therapeutics to help those patients unreliable to respond to the present administrations.

Acknowledgements

The author thankful to Faculty of Science, Janata Junior College, Nagbhid to encouraged for research work. The author also thankful to Visvesvaraya National Institute of Technology, Nagpur to motivated for research work.

Author contribution

The author has alone responsible for writing this article.

Source of funding

None.

Conflict of interest

The authors declare no competing interest.

References

1. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, *et al*. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11;499(7457):214-8.
2. Teng MW, Galon J, Fridman WH, Smyth MJ. From mice to humans: developments in cancer immunoediting. J Clin Invest. 2015 Sep 1;125(9):3338-46.
3. Otsuka A, Dreier J, Cheng PF, Nageli M, Lehmann H, Felderer L, *et al*. Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. Clin Cancer Res. 2015 Mar 15;21(6):1289-97.
4. Otsuka A, Levesque MP, Dummer R, Kabashima K. Hedgehog signaling in basal cell carcinoma. J Dermatol Sci. 2015 May;78(2):95-100.
5. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, *et al*. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016 Aug 25;375(9):819-29.
6. Sarvaria AJ, Madrigal A, Saudemont A. B-cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol. 2017 Aug;14(8):662-74.
7. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, *et al*. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005 Nov 1;25(21):9543-53.
8. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, *et al*. Coregulation of CD8+ T-cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol. 2009 Jan;10(1):29-37.
9. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016 May 17;44(5):989-1004.
10. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, *et al*. PD-1 expression on HIV-specific T-cells is associated with T-cell exhaustion and disease progression. Nature. 2006 Sep 21;443(7109):350-4.
11. Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, Barba L, *et al*. Exhaustion of tumor-specific CD8+ T-cells in metastases from melanoma patients. J Clin Invest. 2011 Jun;121(6):2350-60.
12. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol. 2011;350:17-37.

13. Gardner D, Jeffery LE, Sansom DM. Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. Am J Transplant. 2014 Sep;14(9):1985-91.
14. Speiser DE, Utzschneider DT, Oberle SG, Münz C, Romero P, Zehn D. T-cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol. 2014 Nov;14(11):768-74.
15. Erickson JJ, Gilchuk P, Hastings AK, Tollefson SJ, Johnson M, Downing MB, *et al*. Viral acute lower respiratory infections impair CD8+ T-cells through PD-1. J Clin Invest. 2012 Aug 1;122(8):2967-82.
16. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, *et al*. Biologic activity of cytotoxic T-lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003 Apr 15;100(8):4712-7.
17. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, *et al*. Cancer regression and autoimmunity induced by cytotoxic T-lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7.
18. Chan DV, Gibson HM, Aufiero BM, Wilson AJ, Hafner MS, Mi QS, *et al*. Differential CTLA-4 expression in human CD4+ versus CD8+ T-cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immun. 2014 Jan;15(1):25-32.
19. Leung HT, Bradshaw J, Cleaveland JS, Linsley PS. Cytotoxic T-lymphocyte-associated molecule-4, a high avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. J Biol Chem. 1995 Oct 20;270(42):25107-14.
20. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009 Apr;229(1):12-26.
21. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, *et al*. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011 May 6;332(6029):600-3.
22. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, *et al*. CTLA-4 control over Foxp3+ regulatory T-cell function. Science. 2008 Oct 10;322(5899):271-5.
23. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, *et al*. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995 Nov 10;270(5238):985-8.
24. Gough SC, Walker LS, Sansom DM. CTLA4 gene polymorphism and autoimmunity. Immunol Rev. 2005 Dec;204(1):102-15.
25. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T-cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010 Mar 2;107(9):4275-80.
26. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992 Nov;11(11):3887-95.
27. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999 Aug;11(2):141-51.
28. Sage PT, Francisco LM, Carman CV, Sharpe AH. The receptor PD-1 controls follicular regulatory T-cells in the lymph nodes and blood. Nat Immunol. 2013 Feb;14(2):152-61.
29. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, *et al*. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996 May;8(5):765-72.
30. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA, *et al*. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol. 2008 Nov 15;181(10):6738-46.
31. Pena-Cruz V, McDonough SM, Diaz-Griffero F, Crum CP, Carrasco RD, Freeman GJ. PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen presenting cell activity. J Invest Dermatol. 2010 Sep;130(9):2222-30.
32. Thibult ML, Mamessier E, Gertner-Dardenne J, Pastor S, Just-Landi S, Xerri L, *et al*. PD-1 is a novel regulator of human B-cell activation. Int Immunol. 2013 Feb;25(2):129-37.
33. Lim TS, Chew V, Sieow JL, Goh S, Yeong JP, Soon AL. PD-1 expression on dendritic cells suppresses CD8+ T-cell function and antitumor immunity. Oncoimmunology. 2016 Mar 18;5(3):e1085146.
34. Rodrigues CP, Ferreira ACF, Pinho MP, de Moraes CJ, Bergami-Santos PC, *et al*. Tolerogenic IDO+ dendritic cells are induced by PD-1-expressing mast cells. Front Immunol. 2016 Jan 21;7:9.
35. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, *et al*. PD-L2 is a second ligand for PD-1 and inhibits T-cell activation. Nat Immunol. 2001 Mar;2(3):261-8.
36. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T-cells via PD-1–PD-1 ligand blockade. J Exp Med. 2006 Oct 30;203(10):2223-7.
37. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, *et al*. Blockade of programmed death-1 ligands on dendritic cells enhances T-cell activation and cytokine production. J Immunol. 2003 Feb 1;170(3):1257-66.
38. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T-cell stimulation, but only receptor ligation prevents T-cell activation. J Immunol. 2004 Jul 15;173(2):945-54.
39. Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, *et al*. T-cell costimulatory receptor CD28 is a primary target for PD-1 mediated inhibition. Science. 2017 Mar 24;355(6332):1428-33.
40. Nurieva R, Thomas S, Nguyen T, Martin-Orozco N, Wang Y, Kaja MK, *et al*. T-cell tolerance or function is determined by combinatorial costimulatory signals. EMBO J. 2006 Jun 7;25(11):2623-33.
41. Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice:

implication of PD-1 as a negative regulator for B-cell responses. Int Immunol. 1998 Oct;10(10):1563-72.
42. Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, Tushima F, *et al*. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med. 2003 Jul 7;198(1):71-8.
43. Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, *et al*. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2012 Sep;61(9):1463-72.
44. Huang PY, Guo SS, Zhang Y, Lu JB, Chen QY, Tang LQ, *et al*. Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. Oncotarget. 2016 Mar 15;7(11):13060-8.
45. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, *et al*. Tumor antigen-specific CD8 T-cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009 Aug 27;114(8):1537-44.
46. Chapon M, Randriamampita C, Maubec E, Badoual C, Fouquet S, Wang SF, *et al*. Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. J Invest Dermatol. 2011 Jun;131(6):1300-7.
47. Saito H, Kuroda H, Matsunaga T, Osaki T, Ikeguchi M. Increased PD-1 expression on CD4+ and CD8+ T-cells is involved in immune evasion in gastric cancer. J Surg Oncol. 2013 Apr;107(5):517-22.
48. Xiao X, Lao XM, Chen MM, Liu RX, Wei Y, Ouyang FZ, *et al*. PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 2016 May;6(5):546-59.
49. Gordon SR, Roy LM, Ben WD, Gregor H, Benson MG, Melissa NM, *et al*. PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity. Nature. 2017 May 25;545(7655):495-9.
50. Honda Y, Otsuka A, Ono S, Yamamoto Y, Seidel JA, Morita S, *et al*. Infiltration of PD-1 positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. Oncoimmunology. 2016 Oct 27;6(1):e1253657.
51. Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, *et al*. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer. 2010 Apr 1;116(7):1757-66.
52. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, *et al*. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum resistant ovarian cancer. J Clin Oncol. 2015 Dec 1;33(34):4015-22.
53. Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata. Cancer. 2007 Apr 15;109(8):1499-505.
54. Zhang Y, Kang S, Shen J, He J, Jiang L, Wang W, *et al*. Prognostic significance of programmed cell death 1 (PD-1) or PD-1 ligand 1 (PD-L1) expression in epithelial-originated cancer: a meta-analysis. Medicine. 2015 Feb;94(6):e515.
55. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, *et al*. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 2;373(1):23-34.
56. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, *et al*. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13.
57. Ansell SM, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, *et al*. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 Jan 22;372(4):311-9.
58. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, *et al*. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016 Nov 10;375(19):1856-67.
59. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, *et al*. Nivolumab versus docetaxel in advanced non-squamous non-small cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39.
60. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, *et al*. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer. N Engl J Med. 2015 Jul 9;373(2):123-35.
61. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, *et al*. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015 Jun 25;372(26):2521-32.
62. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, *et al*. PD-1 Blockade with pembrolizumab in advanced Merkel cell carcinoma. N Engl J Med. 2016 Jun 30;374(26):2542-52.
63. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, *et al*. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med. 2015 May 21;372(21):2018-28.
64. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, *et al*. Pembrolizumab versus chemotherapy for PD-L1 positive non-small cell lung cancer. N Engl J Med. 2016 Nov 10;375(19):1823-33.
65. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, *et al*. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011 Jun 30;364(26):2517-26.
66. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, *et al*. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10;31(5):616-22.
67. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, *et al*. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (Check Mate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016 Jul;17(7):883-95.
68. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, *et al*. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015 Apr 24;348(6230):124-8.
69. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, *et al*. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014 Jul 10;371(23):2189-99.

70. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, *et al*. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27;515(7528):568-71.
71. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, *et al*. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res. 2012 Oct 15;72(20):5209-18.
72. Nonomura Y, Otsuka A, Nakashima C, Seidel JA, Kitoh A, Dainichi T, *et al*. Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients. Oncoimmunology. 2016 Nov 15;5(12):e1248327.
73. Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, *et al*. Defining CD8+ T-cells that provide the proliferative burst after PD-1 therapy. Nature. 2016 Sep 22;537(7620):417-21.
74. Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, *et al*. Rescue of exhausted CD8 T-cells by PD-1 targeted therapies is CD28-dependent. Science. 2017 Mar 24;355(6332):1423-7.
75. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, *et al*. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2017 Feb 23;168(3):542.
76. Ribas A, Dummer R, Puzanov I, Vander-Walde A, Andtbacka RHI, Michielin O, *et al*. Oncolytic virotherapy promotes intra-tumoral T-cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017 Sep 21;170(6):1109.e-19.e.
77. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, *et al*. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015 Nov 27;350(6264):1084-9.
78. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, *et al*. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 Jan 5;359(6371):97-103.